Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01182844|
Recruitment Status : Completed
First Posted : August 17, 2010
Last Update Posted : June 4, 2015
Vanessa Stadlbauer-Koellner, MD
Information provided by (Responsible Party):
Vanessa Stadlbauer-Koellner, MD, Medical University of Graz
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||November 2010|
|Actual Study Completion Date :||December 2010|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Stadlbauer V, Leber B, Lemesch S, Trajanoski S, Bashir M, Horvath A, Tawdrous M, Stojakovic T, Fauler G, Fickert P, Högenauer C, Klymiuk I, Stiegler P, Lamprecht M, Pieber TR, Tripolt NJ, Sourij H. Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study. PLoS One. 2015 Oct 28;10(10):e0141399. doi: 10.1371/journal.pone.0141399. eCollection 2015.
Leber B, Tripolt NJ, Blattl D, Eder M, Wascher TC, Pieber TR, Stauber R, Sourij H, Oettl K, Stadlbauer V. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr. 2012 Oct;66(10):1110-5. doi: 10.1038/ejcn.2012.103. Epub 2012 Aug 8.